liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases
Karolinska University Hospital, Sweden .
Länssjukhuset Sundsvall-Härnösand County Hospital, Sundsvall, Sweden, Umeå University Hospital, Sweden.
Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK.
Derriford Hospital, Plymouth, UK.
Show others and affiliations
2013 (English)In: Clinical Genitourinary Cancer, ISSN 1558-7673, Vol. 11, no 1, 20-26 p.Article in journal (Refereed) Published
Abstract [en]

In this 24-month follow-up of a phase II study in patients with castration-resistant prostate cancer (CRPC) and bone metastases, radium-223 (4 injections of 50 kBq/kg every 4 weeks [n = 33]) improved median overall survival vs. matching placebo (n = 31) (65.3 vs. 46.4 weeks, respectively; log-rank P = .056), with no long-term safety concerns. Data suggest that treatment of bone disease with radium-223 has survival benefits. less thanbrgreater than less thanbrgreater thanBackground: This phase II randomized, placebo-controlled study was conducted to evaluate efficacy and safety of radium-223 in patients with castration-resistant prostate cancer (CRPC) and painful bone metastases. Twelve-and 18-month survival results were reported previously. Here we report 24-month overall survival (OS) and safety data from the period 12 to 24 months after the first injection of study medication. Methods: Patients with CRPC and bone pain were randomized 1: 1 to receive 4 injections of radium-223 (50 kBq/kg [n = 33]) or placebo (n = 31) after external-beam radiotherapy; each injection was given every 4 weeks. Endpoints for this report were 24-month OS, long-term safety, and treatment-related adverse events (AEs) occurring in the 12- to 24-month period. Results: After 24 months, 10 (30%) patients were alive in the radium-223 group compared with 4 patients (13%) in the placebo group. Patients who received at least 1 dose of study medication had a median OS of 65 weeks in the radium-223 group vs. 46 weeks in the placebo group (log-rank P = .056). The hazard ratio (HR) for OS, adjusted for baseline covariates, was 0.476 (95% confidence interval [CI], 0.258-0.877; Cox regression P = .017). The most frequent cause of death for both arms was disease progression. There were no reports of treatment-related AEs or long-term hematologic toxicity during the 12- to 24-month follow-up. Conclusion: Radium-223 had a highly favorable safety profile, with no evidence of second malignancies at 24-month follow-up. The significant improvement in OS observed in patients receiving radium-223 vs. placebo suggests that treatment of bone disease with radium-223 has survival benefits. Clinical Genitourinary Cancer, Vol. 11, No. 1, 20-6

Place, publisher, year, edition, pages
Elsevier, 2013. Vol. 11, no 1, 20-26 p.
Keyword [en]
Alpha-pharmaceutical, Castration-resistant prostate cancer, Overall survival, Targeted alpha-emitter
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-90187DOI: 10.1016/j.clgc.2012.07.002ISI: 000315276200004OAI: diva2:613157

Funding Agencies|Algeta ASA, Oslo, Norway||Bayer HealthCare Pharmaceuticals||

Available from: 2013-03-26 Created: 2013-03-21 Last updated: 2013-04-05

Open Access in DiVA

No full text

Other links

Publisher's full text
By organisation
Östergötlands Läns Landsting
In the same journal
Clinical Genitourinary Cancer
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 42 hits
ReferencesLink to record
Permanent link

Direct link